(Alliance News) - GSK PLC on Friday said its respiratory syncytial virus vaccine, Arexvy, has gained an age indication expansion from the US Food & Drug Administration. Read More
(Alliance News) - GSK PLC on Monday announced a global licence deal with Alfasigma Spa for the worldwide rights for linerixibat, an investigational treatment for cholestatic pruritus in primary biliary cholangitis. Read More
(Alliance News) - AstraZeneca secures US priority review for Enhertu, GSK agrees linerixibat deal with Alfasigma, while AdvancedAdvT rules out M&C Saatchi bid. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - GSK PLC on Thursday reported positive regulatory momentum in Japan and China, where two of its drugs have been accepted for review. Read More
(Alliance News) - GSK PLC on Wednesday said it has agreed to buy Canada-based clinical stage biopharmaceutical firm 35Pharma Inc for USD950 million in cash. Read More
(Alliance News) - Stock prices in Europe moved lower in early dealings on Monday, with enthusiasm at the start of the week tempered by tariff uncertainty, as US President Donald Trump hit out at a Supreme Court ruling and announced new trade curbs. Read More
GSK PLC - London-based pharmaceuticals company - Independent Non-Executive Director Wendy Becker buys 3,334 shares, at GBP22.19, worth GBP73,990, on Friday in London. Read More
(Alliance News) - GSK PLC on Tuesday announced the beginning of the fourth tranche of a GBP2 billion buyback programme, worth GBP450 million. Read More
(Alliance News) - NatWest beats annual earnings expectations and boosts shareholder returns, while AstraZeneca reports positive late-stage trial data for Breztri in asthma, as UK retail footfall improves from a weak Christmas period but remains below last year's levels. Read More
(Alliance News) - GSK PLC on Tuesday said its respiratory syncytial virus vaccine Arexvy has been accepted for review by China's Center for Drug Evaluation for adults aged 60 and over. Read More
GSK PLC - London-based pharmaceuticals company - GSK Non-Executive Chair Jonathan Symonds buys 2,500 shares, at a price of GBP21.14, worth GBP52,850, on Thursday in London. Read More